Copeptin, a marker of vasopressin, in abdominal obesity, diabetes and microalbuminuria: the prospective Malmö Diet and Cancer Study cardiovascular cohort
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
BACKGROUND: High plasma copeptin (copeptin), the C-terminal fragment of arginine vasopressin pro-hormone, has been associated with the metabolic syndrome (MetS), diabetes mellitus (DM) development and nephropathy. Here we tested whether elevated copeptin level is associated with later development of the MetS, its individual components and microalbuminuria. METHODS: We analysed copeptin at baseline (1991-1994) in the population-based Malmö Diet and Cancer Study cardiovasular cohort and re-examined 2064 subjects 15.8 years later (mean age 72.8 years, 59% women) with oral glucose tolerance test and measurement of MetS and its individual components. RESULTS: After age and sex adjustment, increasing quartiles of copeptin at baseline (the lowest quartile as reference) were associated with MetS (P for trend=0.008), incident abdominal obesity (P for trend=0.002), DM (P for trend=0.001) and microalbuminuria (P for trend=0.002). After additional adjustment for all the MetS components at baseline, increasing copeptin quartiles predicted incident abdominal obesity (odds ratios 1.55, 1.30 and 1.59; P for trend=0.04), DM (odds ratios 1.18, 1.32 and 1.46; P for trend=0.04) and microalbuminuria (odds ratios 1.05, 1.08 and 1.65; P for trend=0.02) but not MetS (P for trend=0.19) at the reexamination. Further, the relationship between copeptin and microalbuminuria was independent of baseline C-reactive protein, incident DM and incident hypertension. CONCLUSION: Copeptin independently predicts DM and abdominal obesity but not the cluster of MetS. Apart from predicting DM and abdominal obesity, elevated copeptin signals increased risk of microalbuminuria. Interestingly, the association between copeptin and later microalbuminuria was independent of both prevalent and incident DM and hypertension. Our findings suggest a relationship between a dysregulated vasopressin system and cardiometabolic risk, which could have implications for risk assessment and novel preventive treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Science review: Vasopressin and the cardiovascular system part 1--receptor physiology.
(2003) · Critical Care · doi:10.1186/cc2337 · Cited by 356
Plasma Copeptin and the Risk of Diabetes Mellitus
Enhörning, S., Wang, T. J., Nilsson, P. M., Almgren, P., Hedblad, B., Berglund, G., Struck, J., Morgenthaler, N. G., Bergmann, A., Lindholm, E., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.909663 · Cited by 299
Self-citationBardoux, P., Martin, H., Ahloulay, M., Schmitt, F., Bouby, N., Trinh-Trang-Tan, M.-M., & Bankir, L. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.18.10397 · Cited by 138
Self-citationBardoux, P. (2003) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/18.3.497 · Cited by 136
Stimulation by vasopressin, angiotensin and oxytocin of gluconeogenesis in hepatocyte suspensions
Whitton, P. D., Rodrigues, L. M., & Hems, D. A. (1978) · Biochemical Journal · doi:10.1042/bj1760893 · Cited by 123
Meijer, E., Bakker, S. J. L., Halbesma, N., de Jong, P. E., Struck, J., & Gansevoort, R. T. (2010) · Kidney International · doi:10.1038/ki.2009.397 · Cited by 123
Self-citationAlteration of Glucose Homeostasis in V1a Vasopressin Receptor-Deficient Mice
Aoyagi, T., Birumachi, J.-I., Hiroyama, M., Fujiwara, Y., Sanbe, A., Yamauchi, J., & Tanoue, A. (2007) · Endocrinology · doi:10.1210/en.2006-1315 · Cited by 113
The nature of the hepatic receptors involved in vasopressin-induced glycogenolysis
Keppens, S., & De Wulf, H. (1979) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/0304-4165(79)90371-4 · Cited by 98
Glucocorticoids Increase Vasopressin V1b Receptor Coupling to Phospholipase C
Rabadan-Diehl, C., & Aguilera, G. (1998) · Endocrinology · doi:10.1210/endo.139.7.6121 · Cited by 78
Cited by
Vasopressin: a novel target for the prevention and retardation of kidney disease?
Bankir, L., Bouby, N., & Ritz, E. (2013) · Nature Reviews Nephrology · doi:10.1038/nrneph.2013.22 · Cited by 214
Self-citationPlasma Copeptin and Renal Outcomes in Patients With Type 2 Diabetes and Albuminuria
Velho, G., Bouby, N., Hadjadj, S., Matallah, N., Mohammedi, K., Fumeron, F., Potier, L., Bellili-Munoz, N., Taveau, C., Alhenc-Gelas, F., et al. (2013) · Diabetes Care · doi:10.2337/dc13-0683 · Cited by 89
“We also found copeptin levels to be higher inmen than in women as previously observed (8,18,26).”
BackgroundResultSelf-citationTaskin, M. I., Bulbul, E., Adali, E., Hismiogulları, A. A., & Inceboz, U. (2015) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2015.03.006 · Cited by 36
“There are recent studies that associate diabetes mellitus, cardiovascular risk, central obesity, and copeptin levels [12–14].”
BackgroundKarbek, B., Ozbek, M., Karakose, M., Topaloglu, O., Bozkurt, N., Cakır, E., Aslan, M., & Delibasi, T. (2014) · Journal of Ovarian Research · doi:10.1186/1757-2215-7-31 · Cited by 35
Asferg, C. L., Andersen, U. B., Linneberg, A., Goetze, J. P., & Jeppesen, J. L. (2014) · Diabetic Medicine · doi:10.1111/dme.12411 · Cited by 26
Frøssing, S., Nylander, M., Aziz, M., Skouby, S. O., Kistorp, C., & Faber, J. (2017) · Gynecological Endocrinology · doi:10.1080/09513590.2016.1202915 · Cited by 3
“Copeptin levels are elevated in heart failure, acute coronary syndrome [12] and T2D, especially if renal complications are present [13].”
Background
Metadata
- Authors
- Enhörning, S., Bankir, L., Bouby, N., Struck, J., Hedblad, B., Persson, M., Morgenthaler, N. G., Nilsson, P. M., & Melander, O.
- Venue
- International Journal of Obesity
- Published
- 2012-05-22
- Volume
- 37
- Issue
- 4
- Pages
- 598-603
- ISSN
- 0307-0565 (ISSN-L)
- 1476-5497
- OpenAlex
- W2056587840
- Cited by
- 192
- References
- 12
- FWCI
- 9.05
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.